Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of CT-3505 versus crizotinib in treatment-naive ALK-positive non-small cell lung cancer
CTR20240005Phase 3Active
- Sponsor
- Shouyao Holdings
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ficonalkib, crizotinib in non-small cell lung cancer (NSCLC), sponsored by Shouyao Holdings. Started Mar 2024; status: active.
02
Drugs
ficonalkibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20240005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240005.